BioRestorative Therapies enters CFO employment agreement with $175K salary, stock option grant

BioRestorative Therapies, Inc.

CFO Robert E. Kristal employment agreement effective Nov 4, 2021, term through Nov 4, 2022.
Annual salary of $175,000; eligible for discretionary bonus up to 30% of salary.
Granted 10-year option to purchase 10,490 shares at $13.50 per share.
Severance: if terminated without cause or resigns for good reason, receives lesser of remaining salary or 25% of current salary, paid over 3 months.
One-year post-employment non-compete covering stem-cell therapy businesses in the US.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.